ASTRAZEN - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.5
| Stock Code | ASTRAZEN | Market Cap | 20,590 Cr. | Current Price | 8,236 ₹ | High / Low | 10,691 ₹ |
| Stock P/E | 99.0 | Book Value | 320 ₹ | Dividend Yield | 0.39 % | ROCE | 33.4 % |
| ROE | 23.6 % | Face Value | 2.00 ₹ | DMA 50 | 8,417 ₹ | DMA 200 | 8,562 ₹ |
| Chg in FII Hold | 0.07 % | Chg in DII Hold | 0.24 % | PAT Qtr | 31.6 Cr. | PAT Prev Qtr | 58.1 Cr. |
| RSI | 45.8 | MACD | -24.0 | Volume | 5,830 | Avg Vol 1Wk | 9,188 |
| Low price | 7,552 ₹ | High price | 10,691 ₹ | PEG Ratio | 2.29 | Debt to equity | 0.04 |
| 52w Index | 21.8 % | Qtr Profit Var | -42.3 % | EPS | 80.4 ₹ | Industry PE | 30.9 |
📊 ASTRAZEN shows strong fundamentals with high ROE (23.6%) and ROCE (33.4%), supported by low debt (0.04). However, the stock trades at a steep valuation with a P/E of 99.0 compared to the industry average of 30.9, and a PEG ratio of 2.29, indicating expensive growth. Dividend yield is modest at 0.39%, making it less appealing for income-focused investors.
💡 Ideal Entry Zone: ₹7,550 – ₹7,800, closer to its recent low, as current valuations are stretched. RSI at 45.8 suggests neutral momentum, while MACD is negative, hinting at short-term weakness.
📈 Exit / Holding Strategy: If already holding, consider a long-term horizon (3–5 years) given strong ROE/ROCE and low debt. However, monitor quarterly earnings (recent -42.3% decline in PAT). Partial profit booking near ₹10,500+ is advisable, while retaining a core position for long-term compounding.
✅ Positive
- Strong ROE (23.6%) and ROCE (33.4%).
- Low debt-to-equity ratio (0.04).
- Institutional interest with FII (+0.07%) and DII (+0.24%) increases.
⚠️ Limitation
- High P/E (99.0) compared to industry average (30.9).
- PEG ratio (2.29) signals overvaluation.
- Low dividend yield (0.39%).
📉 Company Negative News
- Quarterly profit fell sharply (-42.3%).
- EPS growth not aligned with high valuation multiples.
📈 Company Positive News
- Strong capital efficiency with high ROCE and ROE.
- Stable institutional buying interest.
🏭 Industry
- Industry P/E is 30.9, much lower than ASTRAZEN’s 99.0.
- Healthcare sector remains defensive with steady demand.
🔎 Conclusion
ASTRAZEN is fundamentally strong but currently overvalued. Ideal entry is near ₹7,550–₹7,800. Long-term investors can hold with patience, but short-term traders should consider profit booking near highs. Monitoring quarterly earnings and valuation metrics is essential for sustained conviction.